Preview

Rational Pharmacotherapy in Cardiology

Advanced search

TENEKTEPLASE: NEW POSSIBILITIES FOR SYSTEMIC THROMBOLYTIC THERAPY OF ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION

https://doi.org/10.20996/1819-6446-2010-6-6-837-842

Full Text:

Abstract

Possibilities to use and advantages of a new tissue plasminogen activator (tenekteplase) in patients with acute coronary syndrome (ACS) with ST segment elevation are discussed. The main factor of tenekteplase successful implementation is the time. Comparative studies of tenekteplase and other tissue plasminogen activator are presented. Efficacy of thrombolytic therapy and percutaneous coronary interventions is compared. Data from multicenter randomized clinical trials about combined use of tenekteplase and enoxaparin and unfractionated heparin in the hospital is discussed. Data about safety of tenekteplase in treatment of ACS with ST segment elevation is given.

About the Authors

N. A. Novikova
I.M. Setchenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991


A. E. Udovichenko
I.M. Setchenov First Moscow State Medical University
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991


References

1. ECS Guidelines: Management of acute myocardial infarction in patients presenting with persistent STsegment elevation. Eur Heart J 2008; 29(23): 2909-2946

2. Boersma E., Maas A.C., Deckers J.W., Simoons M.L. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348(9030): 771-775

3. Tsikouris J.P., Tsikouris A.P. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 2001;21:207–217.

4. Vakili B.A., Kaplan R., Brown D.L. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation 2001; 104: 2171–2176.

5. Collen D., Stassen J.M., Yasuda T. et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994;72:98–104.

6. Cannon C.P., McCabe C.H., Gibson C.M. et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351–356.

7. Cannon C.P., Gibson C.M., McCabe C.H. et al. TNK-tissue plasminogen activator compared with frontloaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805–2814.

8. Antman E.M., Hand M., Armstrong P.W. et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296–329.

9. Van de Werf F., Cannon C.P., Luyten A. et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activatorin acute myocardial infarction:theASSENT-1trial. TheASSENT-1Investigators. Am Heart J 1999;137:786–91.

10. Giugliano R.P., McCabe C.H., Antman E.M. et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001;141:742–750.

11. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial.Assessment ofthe Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716–722.

12. Van de Werf F., Barron H.V., Armstrong P.W. et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin- specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22:2253–2261.

13. Melandri G., Vagnarelli F., Calabrese D. et al. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vascular Health and Risk Management 2009: 5; 249-256

14. Sinnaeve P.A., Alexander J.B., Belmans A.C. et al. One-year follow-up of the ASSENT-2 trial: A double-blind,randomized comparison of single- bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST- elevation acute myocardial infarction. Am Heart J 2003;146:27–32.

15. Sabatine M.S., Cannon C.P., Gibson C.M. et al; the CLARITY-TIMI 28 Investigators. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005;352:1179–1189.

16. Antman E.M., Morrow D.A., McCabe C.H. et al; the ExTRACT-TIMI 25 Investigators. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. N Engl J Med 2006;354:1477–1488.

17. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605–613.

18. Antman E.M., Louwerenburg H.W., Baars H.F. et al., the ENTIRE-TIMI 23 Investigators. Enoxaparin asAdjunctiveAntithrombin Therapy for ST-ElevationMyocardial Infarction: Results ofthe ENTIRE- Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642–1649.

19. Kaul P., Armstrong P.W., Cowper P.A. et al. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. Am Heart J 2005;149:637–644.

20. Giugliano R.P., Roe M.T., Harrington R.A. et al. Combination reperfusion therapy with eptifibatide and reduced dose tenecteplase for ST-elevation myocardial infarction: Results ofthe integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase IIAngiographic urial.JAm Coll Cardiol 2003;41:1251– 1260.

21. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905–1914.

22. Wallentin L., Goldstein P., Armstrong P.W. et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135–142.

23. Armstrong P.W., Chang W.C., Wallentin L. et al. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. CMAJ 2006;174:1421–1426.

24. Le May M.R., Wells G.A., Labinaz M. et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;46:417–424.

25. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367:569–578.

26. Armstrong P.W., WEST Steering Committee. A comparison of pharma- cologic therapy with/without timely coronary intervention vs primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27:1530–1538.

27. Fernandez-Aviles F., Alonso J.J., Pena G. et al. Primary angioplasty vs early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 2007;28:949–960.

28. Boehmer E., Hoffmann P., Abdelnoor M., Arnesen H., Halvorsen S. Efficacy and Safety of Immediate Angioplasty Versus Ischemia-Guided Management After Thrombolysis in Acute Myocardial Infarction in Areas With Very Long Transfer Distances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-Elevation Myocardial Infarction) J Am Coll Cardiol 2010; 55:102-110

29. Goodman S.G., Menon V., Cannon C.P. et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:708S–775S.

30. Kalla K., Christ G., Karnik R. et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006;113:2398–2405.

31. Ting H.H., Rihal C.S., Gersh B.J. et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007;116:729–736.

32. Danchin N., Coste P., Ferrieres J. et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment- elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008;118:268–276.


For citation:


Novikova N.A., Udovichenko A.E. TENEKTEPLASE: NEW POSSIBILITIES FOR SYSTEMIC THROMBOLYTIC THERAPY OF ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION. Rational Pharmacotherapy in Cardiology. 2010;6(6):837-842. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-6-837-842

Views: 374


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)